Clinical Trials · NCT05533632
Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 104
- Start date
- Apr 2022
- Locations
- 3 sites, Chile
- Primary endpoint
- Number of Adverse Events (AEs)